Retatrutide 60mg (GLP-1) x 1 Vial + Injection Water Ample

**For customers shipping to Japan**
As of 2020, if you have paid for an injectable product with tax payment, you will be required to present a Pharmaceutical Inspection Certificate. If you do not have a Pharmaceutical Inspection Certificate, please contact the sender to request a refund.We will notify you once the product arrives, and we will reship it after receiving your payment.**Please note that this product cannot be refunded after it has been sold.

***This product is not eligible for bulk discounts.***

Retatrutide 60mg (GLP-1) x 1 Vial + Injection Water Ample

What is Retatrutide?
Focusing on a New Weight-Loss MechanismEli Lilly has added a third mechanism of action for weight loss, aiming to create a drug more effective than any other GLP-1 drug to date. The company is developing an investigational drug called “retatrutide” that targets GLP-1, GIP, and glucagon receptors. The addition of glucagon receptors as one of the targets is due to glucagon’s ability to promote fat breakdown. Clinical trial results published last year showed that participants receiving retatortide lost more than 17% (approximately 18.6 kg) of body weight over 24 weeks. Over 48 weeks, participants lost an average of 24% (approximately 26.3 kg). This was more effective than any other drug on the market.Why not try this highly effective drug? Experience the amazing benefits for yourself!

How Retatrutide Works
Retatrutide’s power comes from its unique triple-action mechanism. Unlike other drugs, it simultaneously activates three hormone receptors: GLP-1 receptor, GIP receptor, and glucagon receptor (GCGR).

By targeting all three, retatortide can:

Control hunger signals and slow digestion
Shift metabolism
Regulate blood sugar levels
Promote lipolysis

Older weight-loss medications like Wegovy/Ozempic (semaglutide) only target GLP-1, while newer weight-loss medications like Zepbound/Mounjaro (tirzepatide) target both GLP-1 and GIP. retatortide’s triple-receptor approach is why it produces better results.

Retatortide Dosage Guidelines

Starting Dose
Recommended starting doses for retatortide vary across clinical trials and medical sources, as researchers work to find optimal protocols. Common starting doses include:

1-2 mg weekly: Recommended for patients sensitive to side effects or those new to GLP-1 medications.
2.5 mg weekly: Standard starting dose that balances efficacy and tolerability.
A lower starting dose allows the body to gradually adapt, reducing gastrointestinal side effects, such as nausea and dizziness, that commonly occur at the start of treatment.

Titration Schedule
Titration (gradually increasing the dose) is key to retatortide treatment. This helps the body adapt while managing side effects. A typical schedule might look like this:

Weeks 1-4: Starting dose (1-2.5 mg)
Weeks 5-8: Increase to 2.5-5 mg
Weeks 9-12: Increase to 4-10 mg
Weeks 13+: Optionally increase to 8-12 mg depending on tolerance.
Studies have shown a clear association between higher doses and greater weight loss results.

Maintenance Dose
After reaching target weight or optimal response, patients are switched to a maintenance dose. This ensures results are maintained without continued dose increases. Maintenance doses are typically:

5–10 mg weekly for most patients

Up to 12–15 mg weekly for those requiring more intensive treatment

Finding the Optimal Retatortide Dose
Six factors determine your individual dose:

Weight: Heavier individuals generally require a higher initial dose.
Metabolism: Slower metabolizers require a more gradual increase.
Overall Health: Pre-existing conditions, such as diabetes, affect the dose.
Individualized: Adjustments based on side effects and results.
Treatment Goals: Focus on weight loss and metabolic health.
Previous GLP-1 Use: Previous experience may warrant a higher starting dose.
Weight Loss Study Results
Retatortide has proven effective in clinical trials. A pivotal Phase 2 study published in the New England Journal of Medicine established:

After 24 weeks: Weight loss ranged from 7.2% at the lowest dose of retatortide to 17.5% at the highest dose (compared to only 1.6% with placebo). After 48 weeks: Participants on the 12 mg dose lost an average of 24.2% of their starting weight (placebo group: only 2.1%).
Most participants taking retatortide (64-100%) achieved a significant weight loss of 5% or more, while only 27% of placebo recipients achieved this goal.
Managing Retatortide Side Effects
The main side effects of retatortide affect the digestive system.

Nausea
Vomiting
Diarrhea
Bloating
These effects are usually not severe and tend to subside as the body adapts to the medication. Your doctor will gradually increase your dose, especially to minimize these issues.

If side effects become difficult:

Extend your time at your current dose, then increase it.

Talk to your doctor about temporarily reducing your dose.

Discuss specific management techniques with your healthcare provider.